Adel Zakhary
Internal Medicine · Colleyville, TXNPI 1881645414
Payments from drug & device makers
Across 242 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$683
- AstraZeneca$507
- Novo Nordisk$493
- Lilly USA, LLC$304
- AbbVie$248
- Pfizer$215
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,538100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 62 | $683 |
| AstraZeneca | 29 | $507 |
| Novo Nordisk | 35 | $493 |
| Lilly USA, LLC | 22 | $304 |
| AbbVie(2 entities) | 10 | $248 |
| Pfizer | 18 | $215 |
| Arbor Pharmaceuticals, Inc. | 10 | $143 |
| Boehringer Ingelheim | 7 | $141 |
| GSK | 8 | $126 |
| Esperion Therapeutics, Inc. | 6 | $97 |
| Bayer | 4 | $66 |
| Novartis | 4 | $66 |
| Abbott | 3 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Merck | 3 | $45 |
| Amarin Pharma, Inc. | 3 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Johnson & Johnson | 1 | $37 |
| Boston Scientific | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Eisai Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Althera Pharmaceuticals LLC | 2 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
How this compares
$3,556 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 11 | $26,120 |
| JardianceEmpagliflozin | 17 | $19,127 |
| Rosuvastatin Calcium | 74 | $895 |
| Omeprazole | 31 | $709 |
| Gabapentin | 22 | $586 |
| Atorvastatin Calcium | 64 | $527 |
| Labetalol Hcl | 26 | $443 |
| Metformin Hcl | 46 | $384 |
| Levothyroxine Sodium | 49 | $378 |
| Lisinopril | 50 | $361 |
| Amlodipine Besylate | 48 | $327 |
| Olmesartan Medoxomil | 30 | $321 |
| Metoprolol Succinate | 19 | $310 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $307 |
| Losartan Potassium | 36 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $304 | $26,12011 claims |
| Boehringer IngelheimJardiance | $141 | $19,12717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Colleyville
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.